505 related articles for article (PubMed ID: 12839703)
1. How can we predict bacterial eradication?
Jacobs MR
Int J Infect Dis; 2003 Mar; 7 Suppl 1():S13-20. PubMed ID: 12839703
[TBL] [Abstract][Full Text] [Related]
2. Activity of nine oral agents against gram-positive and gram-negative bacteria encountered in community-acquired infections: use of pharmacokinetic/pharmacodynamic breakpoints in the comparative assessment of beta-lactam and macrolide antimicrobial agents.
Peric M; Browne FA; Jacobs MR; Appelbaum PC
Clin Ther; 2003 Jan; 25(1):169-77. PubMed ID: 12637118
[TBL] [Abstract][Full Text] [Related]
3. Achieving bacterial eradication using pharmacokinetic/pharmacodynamic principles.
Dagan R
Int J Infect Dis; 2003 Mar; 7 Suppl 1():S21-6. PubMed ID: 12839704
[TBL] [Abstract][Full Text] [Related]
4. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.
Jacobs MR; Felmingham D; Appelbaum PC; Grüneberg RN;
J Antimicrob Chemother; 2003 Aug; 52(2):229-46. PubMed ID: 12865398
[TBL] [Abstract][Full Text] [Related]
5. Susceptibilities of Haemophilus influenzae, Streptococcus pneumoniae, including serotype 19A, and Moraxella catarrhalis paediatric isolates from 2005 to 2007 to commonly used antibiotics.
Harrison CJ; Woods C; Stout G; Martin B; Selvarangan R
J Antimicrob Chemother; 2009 Mar; 63(3):511-9. PubMed ID: 19174454
[TBL] [Abstract][Full Text] [Related]
6. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
[TBL] [Abstract][Full Text] [Related]
7. Optimisation of antimicrobial therapy using pharmacokinetic and pharmacodynamic parameters.
Jacobs MR
Clin Microbiol Infect; 2001 Nov; 7(11):589-96. PubMed ID: 11737083
[TBL] [Abstract][Full Text] [Related]
8. In vitro activity of cefditoren and other comparators against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis causing community-acquired respiratory tract infections in China.
Yang Q; Xu Y; Chen M; Wang H; Sun H; Hu Y; Zhang R; Duan Q; Zhuo C; Cao B; Liu Y; Yu Y; Sun Z; Chu Y
Diagn Microbiol Infect Dis; 2012 Jun; 73(2):187-91. PubMed ID: 22521692
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models.
Liu P; Rand KH; Obermann B; Derendorf H
Int J Antimicrob Agents; 2005 Feb; 25(2):120-9. PubMed ID: 15664481
[TBL] [Abstract][Full Text] [Related]
10. Multicenter surveillance of antimicrobial resistance of Streptococcus pyogenes, Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis to 14 oral antibiotics.
Hsueh PR; Huang WK; Shyr JM; Lau YJ; Liu YC; Luh KT
J Formos Med Assoc; 2004 Sep; 103(9):664-70. PubMed ID: 15361938
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
Granizo JJ; Giménez MJ; Barberán J; Coronel P; Gimeno M; Aguilar L
Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
[TBL] [Abstract][Full Text] [Related]
12. Results from the Survey of Antibiotic Resistance (SOAR) 2014-16 in Russia.
Torumkuney D; Mayanskiy N; Edelstein M; Sidorenko S; Kozhevin R; Morrissey I
J Antimicrob Chemother; 2018 Apr; 73(suppl_5):v14-v21. PubMed ID: 29659881
[TBL] [Abstract][Full Text] [Related]
13. Optimal antibiotic dosing. The pharmacokinetic-pharmacodynamic interface.
Reed MD
Postgrad Med; 2000 Dec; 108(7 Suppl Contemporaty):17-24. PubMed ID: 19667545
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Thornsberry C; Ogilvie P; Kahn J; Mauriz Y
Diagn Microbiol Infect Dis; 1997 Dec; 29(4):249-57. PubMed ID: 9458982
[TBL] [Abstract][Full Text] [Related]
15. Building in efficacy: developing solutions to combat drug-resistant S. pneumoniae.
Jacobs MR
Clin Microbiol Infect; 2004 Apr; 10 Suppl 2():18-27. PubMed ID: 14759230
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated from community-acquired respiratory tract infections in China: Results from the CARTIPS Antimicrobial Surveillance Program.
Zhang Y; Zhang F; Wang H; Zhao C; Wang Z; Cao B; Du Y; Feng X; Hu Y; Hu B; Ji P; Liu Z; Liu Y; Liao W; Lu J; Sun H; Wang Z; Xu X; Xu X; Yang Q; Yu Y; Zhang R; Zhuo C
J Glob Antimicrob Resist; 2016 Jun; 5():36-41. PubMed ID: 27436464
[TBL] [Abstract][Full Text] [Related]
17. Determination of the antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae, Streptococcus pneumoniae and Moraxella catarrhalis. Canadian Antimicrobial Study Group.
Blondeau JM; Suter M; Borsos S
J Antimicrob Chemother; 1999 Mar; 43 Suppl A():25-30. PubMed ID: 10225568
[TBL] [Abstract][Full Text] [Related]
18. Susceptibilities of Streptococcus pneumoniae and Haemophilus influenzae to 10 oral antimicrobial agents based on pharmacodynamic parameters: 1997 U.S. Surveillance study.
Jacobs MR; Bajaksouzian S; Zilles A; Lin G; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 1999 Aug; 43(8):1901-8. PubMed ID: 10428910
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility patterns for amoxicillin/clavulanate tests mimicking the licensed formulations and pharmacokinetic relationships: do the MIC obtained with 2:1 ratio testing accurately reflect activity against beta-lactamase-producing strains of Haemophilus influenzae and Moraxella catarrhalis?
Pottumarthy S; Sader HS; Fritsche TR; Jones RN
Diagn Microbiol Infect Dis; 2005 Nov; 53(3):225-31. PubMed ID: 16257168
[TBL] [Abstract][Full Text] [Related]
20. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods.
Morrissey I; Robbins M; Viljoen L; Brown DF
J Antimicrob Chemother; 2005 Feb; 55(2):200-8. PubMed ID: 15649996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
